## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Celina Cziepluch et al.

Title: METHOD TO INHIBIT THE

PROPAGATION OF AN UNDESIRED CELL

POPULATION

Unassigned

Appl. No.: 10/568,356

International 8/16/2004

Filing Date:

Examiner:

371(c) Date:

Art Unit: 2811

Confirmation 2717

Number:

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to
Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR \$1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be

Atty. Dkt. No. 085449-0186

appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

## TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

## RELEVANCE OF EACH DOCUMENT

The documents listed on the attached PTO/SB/08 are described in the specification as well as cited in the attached International Search Report for related International Application No. PCT/EP2004/009170.

Please note that WO 2004/030615 listed on the PTO/SB/08 is over 7,000 pages, consisting of Box 2 of 3 and 3 of 3.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date: May 22, 2007

FOLEY & LARDNER LLP Customer Number: 22428 Telephone: (202) 672-5538

Facsimile:

(202) 672-5399

Michele M. Simkin Attorney for Applicant Registration No. 34,717

By Michael MACh

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449/PTO Complete if Known INFORMATION DISCLOSURE Application Number 10/568,356 STATEMENT BY APPLICANT Filing Date February 14, 2006 First Named Inventor Celina Cziepluch Date Submitted: May 22, 2007 Art Unit 2811 (use as many sheets as necessary) Examiner Name Unassigned Sheet 1 of Attomey Docket Number 085449-0186

			U.S. PATENT DO	CUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Cited Document	
		2002/0022221 A1	02/21/2002	Panganiban et al.	
		6,392,014 B1	05/21/2002	Cesbron et al.	
				1	

Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant	T
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i>If known</i> )	MM-DD-YYYY	Applicant of Cited Documents	Passages or Relevant Figures Appear	Т
		WO 01/77168 A2	10/18/2001	Lodes et al.		П
		WO 02/31152 A2	04/18/2002	Baughn et al.		Т
		WO 01/75067 A2	10/11/2001	Drmanac et al.		
		WO 01/73019 A1	10/04/2001	Moarefi et al.		Ι
		WO 2004/030615	04/15/2004	Wu et al.	*Please note this reference is over	
				Box 2 of 3 and Box 3 of 3	7,000 pgs.	╀
						+

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		Kittler et al., "RNA Interference: Gene Silencing In the Fast Lane," Seminars in Cancer Biology 13, (2003), pp. 259-265.	
		Cziepluch et al., "Identification of a Novel Cellular TPR-Containing Protein, SGT, That Interacts with the Nonstructural Protein NS1 of Parvovirus H-1," <i>Journ. Of Virology,</i> (1998), pp. 4149-4156.	
		Fonte et al., "Interaction of Intracellular β Amyloid Peptide with Chaperone Proteins," PNAS, Vol. 99, No. 14, (2002) pp. 9439-9444.	
		Brummelkamp et al., "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells," Vol. 296, Science, 2002, pp. 550-553.	

Examiner Signature	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 003. Draw line through citation if not in conformance and not considered include copy of life from with next communication to applicant. 1 Applicant surique citation designation number (oplicant) customer to USPTO Patient Documents at www.uspto.gov or MPEP 901.04.3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3.). 4 For Japanese patient documents, the indication of the year of the reign of the Emperor must precede the serial number of the patient document. Indication of the year of the reign of the Emperor must precede the serial number of the patient document indir do document by the appropriate symbols as indicated on the document under WIPO Standard ST.161 possible. 6 Applicant is to place a check mark here if English language Translation is attached. USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR.1.14. This collection is estimated to take 2 hours to complete, including the complete this form and/or suppessions for reducing his burden, should be sent to the Chief Information Officer, U.S. Patient and Trademark Office (P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.							
Substitute for form 1449/PTO					Complete if Known		
	INFORMATION	ON DISCLO	SURE	Application Number	10/568,356		
1	STATEMEN <sup>*</sup>	T BY APPLI	CANT	Filing Date	February 14, 2006		
1	Date Submit	tod: May 22	2007	First Named Inventor	Celina Cziepluch		
ŀ	Date Submit	ieu. May 22	, 2007	Art Unit	2811		
	(use as many sheets as necessary)			Examiner Name	Unassigned		
Sheet	2	of	2	Attomey Docket Number	085449-0186		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		Sui et al., "A DNA Vector-Based RNAi Technology to Suppress Gene Expression in Mammalian Cells," PNAS, Vol. 99, No. 8, 2002, pp. 5515-5520.	
		Morris et al., "Translocating Peptides and Proteins and Their Use for Gene Delivery," Curr. Opin. Biotech, Vol. 11(5), 2000, pp. 461-466.	
		Kordes et al, "Isolation and Characterization of Human SGT and Identification of Homologues in Saccharomyces Cerevisiae and Caenorhabditis Elegans," Genomics 52, 1998, pp. 90-94.	

Examiner Signature	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not clatation is in conformance with MPEP 698. Draw line through classon if not in conformance and not considered, include copy of like form with next communication to applicant. 1 Applicant is unique citized nestignation unmarbe (politional) to USPTO Patient Documents at www.uspto.gov or MPEP 901.04.3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).4 For Japanese patient documents, the findication of the year of the reign of the Emperor must precede the serial number of the patent document of document under WIPO Standard ST.61 for subject to the patient serial number of the patent document. For displacing the patient serial patient serial number of the patent document. The patient described is a standard on the document under WIPO Standard ST.61 for subject to the patient serial number of the patent document. The patient described is not information is required by 35 LS.C. 122 and 37 CFR.11.4 This collection is estimated to take 2 hours to complete, including patients, prompting, and submitting the completed application from 2 hours and application from 10 hours and 1